An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of two different formulations of GSK163090 and the effect of food on the pharmacokinetics of a tablet formulation in healthy male and female volunteers.

Trial Profile

An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of two different formulations of GSK163090 and the effect of food on the pharmacokinetics of a tablet formulation in healthy male and female volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs GSK 163090 (Primary)
  • Indications Anxiety disorders; Depression
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jun 2008 Actual completion date added as Nov 2007 as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top